CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for RetinalGenix Technologies Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

RetinalGenix Technologies Inc
1450 North Mcdowell Boulevard, Suite 150
Phone: (415) 578-9583p:415 578-9583 PETALUMA, CA  94954  United States Ticker: RTGNRTGN
Business Summary
RetinalGenix Technologies Inc. is an ophthalmic research and development company. The Company is focused on creating solutions to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders and to enable the early detection and treatment of multiple systemic diseases through a combination of therapeutic medications and medical device technologies. The Company is focused on preventing vision loss and blindness due to ocular diseases, including diabetic retinopathy and maculopathy, in its first two devices: Retinal Imaging Screening Device and RetinalCam. Retinal Imaging Screening Device is a portable, retinal imaging system providing a wide field of view without requiring pupil dilation. RetinalCam is an in-home/remote location patient-activated monitoring and imaging device offering real time communication and alerting system for physicians available 24/7. The Company is also engaged in the development of its product candidates: RTG-2023 and RTG-2024.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
3841 Surgical and medical instruments and apparatus
8731 Commercial physical and biological research
3851 Ophthalmic goods

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Director JerryKatzman 68 12/1/2018 8/1/2018
Interim Chief Financial Officer VirenderAhluwalia 65 11/30/2023 11/30/2023
Director DessislavaBoneva 52 12/4/2023 12/4/2023
Independent Director HerbertGould 93 4/1/2019 4/1/2019
Independent Director VinayMehindru 55 7/25/2022 7/25/2022

Business Names
Business Name
DNA/GPS Inc.
RTGN

General Information
Outstanding Shares: 17,785,478 (As of 3/26/2024)
Shareholders: 112
Stock Exchange: OTC
Federal Tax Id: 823936890
Fax Number: (302) 645-1280


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024